NFKB1 and metabolic dysfunction-associated steatohepatitis: By combining transcriptome analysis with network pharmacology analysis, we demonstrated that the therapeutic mechanism of XYS in NASH-related liver fibrosis involves the regulation of STAT3, NFκB, and PPARγ and their downstream genes and the intervention of the ECM, inflammation, and metabolism.